Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SS)
- Previous Close
53.99 - Open
54.28 - Bid 56.36 x --
- Ask 56.38 x --
- Day's Range
54.01 - 56.84 - 52 Week Range
32.72 - 59.71 - Volume
4,329,052 - Avg. Volume
3,592,482 - Market Cap (intraday)
25.902B - Beta (5Y Monthly) 0.24
- PE Ratio (TTM)
-- - EPS (TTM)
-1.96 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Dizal (Jiangsu) Pharmaceutical Co., Ltd. discovers, develops, and commercializes medicines in the areas of cancer and immunological diseases. It develops JAUKPO, which is in Phase II clinical trials for the treatment of hematological malignancy and immunological diseases; DZD8586 that is in Phase I for the treatment of hematological malignancy; ZEGFROVY, which is in Phase II clinical trials for the treatment of solid tumors; DZD1516 that is in Phase II clinical trials for the treatment of solid tumors; and DZD2269, which is in Phase I clinical trials for the treatment of solid tumors. The company was founded in 2017 and is based in Shanghai, China.
www.dizalpharma.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 688192.SS
View MorePerformance Overview: 688192.SS
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 688192.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 688192.SS
View MoreValuation Measures
Market Cap
25.90B
Enterprise Value
26.43B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
53.46
Price/Book (mrq)
1.40k
Enterprise Value/Revenue
60.32
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-237.73%
Return on Assets (ttm)
-36.27%
Return on Equity (ttm)
-133.26%
Revenue (ttm)
360.39M
Net Income Avi to Common (ttm)
-856.77M
Diluted EPS (ttm)
-1.96
Balance Sheet and Cash Flow
Total Cash (mrq)
808.3M
Total Debt/Equity (mrq)
206.74%
Levered Free Cash Flow (ttm)
-519.22M